HBW Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Euro Q4 Earnings Preview: GSK, Sanofi, Bayer And Reckitt

Executive Summary

Major Europe-based consumer health players GSK, Sanofi, Bayer and Reckitt feature in this earnings preview, which highlights what to look out for as these four firms report their Q4 and annual results over the coming weeks.

You may also be interested in...

P&G's Feminine Care Sales Up As Incontinence, Menstrual Products Get Superiority Attention

Procter & Gamble CEO Jon Moeller and and feminine products chief Jennifer Davis outline firm's strategies and focus areas in sustainability and superiority in 2022.  While more than half consumers are interested in natural or more sustainable products, few will settle for lesser product performance, Davis said. But  they appear willing to pay a premium for products made with sustainable materials.

Sanofi Pairs Up With Non-Profit Protas In Quest To Cut Clinical Trial Costs

The French major has committed up to £5m for non-profit Protas, which aims to facilitate large clinical studies at a fraction of the usual price and form more pharmaceutical collaborations down the line.

With Investor Support Thin On The Ground, Unilever Won't Up Bid For GSK Consumer Healthcare

Unilever's decision not to increase its £50bn bid for GSK Consumer Healthcare has been widely welcomed by analysts. But they warn that the aborted move for GSK has damaged investor confidence in Unilever’s management.

Related Content





Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts